S&P 500   4,560.65 (+0.35%)
DOW   35,740.74 (+0.18%)
QQQ   376.08 (+0.53%)
AAPL   148.28 (-0.28%)
MSFT   307.96 (-0.39%)
FB   323.95 (-0.20%)
GOOGL   2,739.57 (-0.43%)
TSLA   972.31 (+6.88%)
AMZN   3,303.72 (-0.95%)
NVDA   230.59 (+1.47%)
BABA   175.17 (-1.42%)
NIO   40.66 (+4.58%)
CGC   13.28 (-0.75%)
GE   105.58 (+1.47%)
AMD   121.53 (+1.43%)
MU   68.78 (+1.88%)
T   25.43 (-0.24%)
F   16.12 (-0.98%)
ACB   7.11 (+0.57%)
DIS   170.55 (+0.67%)
PFE   42.85 (-0.72%)
BA   212.41 (-0.26%)
AMC   37.67 (+2.92%)
S&P 500   4,560.65 (+0.35%)
DOW   35,740.74 (+0.18%)
QQQ   376.08 (+0.53%)
AAPL   148.28 (-0.28%)
MSFT   307.96 (-0.39%)
FB   323.95 (-0.20%)
GOOGL   2,739.57 (-0.43%)
TSLA   972.31 (+6.88%)
AMZN   3,303.72 (-0.95%)
NVDA   230.59 (+1.47%)
BABA   175.17 (-1.42%)
NIO   40.66 (+4.58%)
CGC   13.28 (-0.75%)
GE   105.58 (+1.47%)
AMD   121.53 (+1.43%)
MU   68.78 (+1.88%)
T   25.43 (-0.24%)
F   16.12 (-0.98%)
ACB   7.11 (+0.57%)
DIS   170.55 (+0.67%)
PFE   42.85 (-0.72%)
BA   212.41 (-0.26%)
AMC   37.67 (+2.92%)
S&P 500   4,560.65 (+0.35%)
DOW   35,740.74 (+0.18%)
QQQ   376.08 (+0.53%)
AAPL   148.28 (-0.28%)
MSFT   307.96 (-0.39%)
FB   323.95 (-0.20%)
GOOGL   2,739.57 (-0.43%)
TSLA   972.31 (+6.88%)
AMZN   3,303.72 (-0.95%)
NVDA   230.59 (+1.47%)
BABA   175.17 (-1.42%)
NIO   40.66 (+4.58%)
CGC   13.28 (-0.75%)
GE   105.58 (+1.47%)
AMD   121.53 (+1.43%)
MU   68.78 (+1.88%)
T   25.43 (-0.24%)
F   16.12 (-0.98%)
ACB   7.11 (+0.57%)
DIS   170.55 (+0.67%)
PFE   42.85 (-0.72%)
BA   212.41 (-0.26%)
AMC   37.67 (+2.92%)
S&P 500   4,560.65 (+0.35%)
DOW   35,740.74 (+0.18%)
QQQ   376.08 (+0.53%)
AAPL   148.28 (-0.28%)
MSFT   307.96 (-0.39%)
FB   323.95 (-0.20%)
GOOGL   2,739.57 (-0.43%)
TSLA   972.31 (+6.88%)
AMZN   3,303.72 (-0.95%)
NVDA   230.59 (+1.47%)
BABA   175.17 (-1.42%)
NIO   40.66 (+4.58%)
CGC   13.28 (-0.75%)
GE   105.58 (+1.47%)
AMD   121.53 (+1.43%)
MU   68.78 (+1.88%)
T   25.43 (-0.24%)
F   16.12 (-0.98%)
ACB   7.11 (+0.57%)
DIS   170.55 (+0.67%)
PFE   42.85 (-0.72%)
BA   212.41 (-0.26%)
AMC   37.67 (+2.92%)
NASDAQ:NRXP

NRx Pharmaceuticals News Headlines

$9.84
-0.06 (-0.61 %)
(As of 10/25/2021 11:46 AM ET)
Add
Compare
Today's Range
$9.22
$9.97
50-Day Range
$6.78
$17.86
52-Week Range
$6.43
$76.99
Volume17,997 shs
Average Volume2.15 million shs
Market Capitalization$529.14 million
P/E RatioN/A
Dividend YieldN/A
Beta0.02

Media Mentions By Week



NRx Pharmaceuticals Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

NRXP
News Sentiment

0.07

0.37

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

NRXP Articles
This Week

3

4

NRXP Articles
Average Week

Get NRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.

NRx Pharmaceuticals (NASDAQ NRXP) News Headlines Today

SourceHeadline
MarketBeat logoNRx Pharmaceuticals (NASDAQ:NRXP) Stock Price Down 5%
americanbankingnews.com - October 21 at 1:33 PM
MarketBeat logoNRx Pharmaceuticals (NASDAQ:NRXP) Trading 8.9% Higher
americanbankingnews.com - October 19 at 2:20 PM
MarketBeat logoNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Drop in Short Interest
americanbankingnews.com - October 18 at 1:52 AM
msn.com logoWhy NRx Pharmaceuticals Stock Is Tumbling Today
msn.com - October 15 at 2:44 PM
MarketBeat logoNRx Pharmaceuticals (NASDAQ:NRXP) Trading Down 8.7%
americanbankingnews.com - October 15 at 12:41 PM
markets.businessinsider.com logoWhy NRX Pharmaceuticals Stock Is Surging Today
markets.businessinsider.com - October 14 at 2:49 PM
msn.com logoWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday
msn.com - October 14 at 2:49 PM
MarketBeat logoNRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Up to $9.44
americanbankingnews.com - October 14 at 11:55 AM
MarketBeat logoNRx Pharmaceuticals Target of Unusually High Options Trading (NASDAQ:NRXP)
americanbankingnews.com - October 14 at 10:52 AM
finance.yahoo.com logoJournal of Infectious Diseases and Treatment Publishes Positive Trial Data of Aviptadil in High Comorbidity Patients Suffering from Critical COVID-19 with Respiratory Failure
finance.yahoo.com - October 14 at 9:48 AM
MarketBeat logoNRx Pharmaceuticals (NASDAQ:NRXP) Shares Gap Down to $10.92
americanbankingnews.com - October 13 at 11:58 AM
uk.finance.yahoo.com logoRelief Reports that its U.S. Collaboration Partner has Announced Progress on Worldwide Commercial Scale Development of ZYESAMI(TM) (aviptadil)
uk.finance.yahoo.com - October 13 at 1:41 AM
markets.businessinsider.com logoWhy NRX Pharmaceuticals Shares Are Rising
markets.businessinsider.com - October 12 at 8:41 PM
nasdaq.com logoNRx Pharma: Data Safety Monitoring Board Finds No New Safety Concerns In ACTIV-3b Trial
nasdaq.com - September 29 at 4:23 PM
finance.yahoo.com logoNRx Pharmaceuticals Announces Improved Survival at One Year in Highly Comorbid COVID-19 Patients Treated with ZYESAMI (aviptadil)
finance.yahoo.com - September 27 at 11:22 AM
msn.com logoIQVIA (IQV) Announces Collaboration With NRx Pharmaceuticals
msn.com - September 14 at 4:12 PM
finance.yahoo.com logoNRx Pharmaceuticals to Participate in H.C. Wainwright 23rd Annual Global Investment Conference
finance.yahoo.com - September 8 at 8:31 AM
markets.businessinsider.com logoNRx : Zyesami Phase 2b/3 Trial Result Shows Relief From Respiratory Distress In Critical COVID-19
markets.businessinsider.com - August 30 at 8:38 AM
finance.yahoo.com logoNRx Pharmaceuticals Announces New Finding from ZYESAMI™ (aviptadil) Phase 2b/3 Clinical Trial Demonstrating Clinically Significant Relief from Respiratory Distress in Critical COVID-19
finance.yahoo.com - August 30 at 8:38 AM
nasdaq.com logoWhat Percentage Of NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Shares Do Insiders Own?
nasdaq.com - August 27 at 10:55 PM
benzinga.com logoWhy NRX Pharmaceuticals Stock Is Trading Higher Today
benzinga.com - August 26 at 4:42 PM
finance.yahoo.com logoNRx Pharmaceuticals to Work with Cardinal Health to Ensure Efficient Distribution of Potential Therapies
finance.yahoo.com - August 26 at 7:05 AM
finance.yahoo.com logoWhat Is The Ownership Structure Like For NRx Pharmaceuticals, Inc. (NASDAQ:NRXP)?
finance.yahoo.com - August 25 at 3:46 PM
bizjournals.com logoMain Line biopharma firm behind Covid-19 therapy raises $30M to advance product line
bizjournals.com - August 24 at 3:58 PM
finance.yahoo.com logoNRx Pharmaceuticals Announces Closing of $30 Million Private Placement
finance.yahoo.com - August 24 at 6:56 AM
finance.yahoo.com logoParticipants in High Dose BriLife™ Investigational Vaccine Trial for COVID-19 Advised Booster Not Necessary
finance.yahoo.com - August 23 at 3:54 PM
nasdaq.com logoWhy NRx Pharmaceuticals Stock Is Sinking Today
nasdaq.com - August 19 at 4:33 PM
msn.com logoWhy NRx Pharmaceuticals Stock Jumped 11.8% Today
msn.com - August 18 at 5:43 PM
finance.yahoo.com logoNRx Pharmaceuticals Announces Positive Safety Report for ZYESAMI™ (aviptadil) in NIH Sponsored ACTIV-3 Critical Care Study in Patients with Life-Threatening COVID-19
finance.yahoo.com - August 18 at 5:43 PM
seekingalpha.com logoNRx Pharmaceuticals, Inc. (NRXP) CEO Jonathan Javitt on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com - August 18 at 7:42 AM
nasdaq.com logoNRX Pharmaceuticals, Inc. Rings The Nasdaq Stock Market Closing Bell
nasdaq.com - August 12 at 4:43 PM
finance.yahoo.com logoNRx Pharmaceuticals to Report Second Quarter 2021 Results August 16, 2021
finance.yahoo.com - August 11 at 11:15 PM
nasdaq.com logoNRX Pharmaceuticals, Inc. Rings the Closing Bell
nasdaq.com - August 10 at 5:50 PM
finance.yahoo.com logoNRx Pharmaceuticals to Ring Nasdaq Closing Bell on August 10, 2021
finance.yahoo.com - August 10 at 7:36 AM
finance.yahoo.com logoNRx Pharmaceuticals Announces Initiation of Phase 2b Trial of BriLife™ Vaccine for Covid-19 in Nation of Georgia
finance.yahoo.com - August 9 at 4:33 PM
msn.com logoCould This Be the Biggest News in Treating Severe COVID So Far?
msn.com - July 31 at 9:00 AM
bizjournals.com logoNRx Pharmaceuticals' Covid-19 therapy secures first emergency use authorization
bizjournals.com - July 28 at 5:17 PM
finance.yahoo.com logoRelief Reports that its U.S. Collaboration Partner has Announced Emergency Use Authorization of Aviptadil in Nation of Georgia
finance.yahoo.com - July 28 at 7:16 AM
realmoney.thestreet.com logoNRx Pharmaceuticals Charts Are Pointed Still Lower
realmoney.thestreet.com - July 27 at 12:43 PM
msn.com logoHere's Why NRx Pharmaceuticals Stock Dropped Monday
msn.com - July 27 at 12:43 PM
finance.yahoo.com logoNRx Pharmaceuticals Announces Emergency Use Authorization of ZYESAMI™ (aviptadil) in Nation of Georgia
finance.yahoo.com - July 27 at 12:43 PM
bizjournals.com logoCovid-19 therapy developer on the Main Line has another strong day on Wall Street
bizjournals.com - July 23 at 6:16 PM
markets.businessinsider.com logoNRX Pharmaceuticals Climbs Higher After FDA News, Could See A Breakout Soon
markets.businessinsider.com - July 23 at 6:16 PM
baystreet.ca logoNRx Rockets on Product Development
baystreet.ca - July 23 at 1:15 PM
markets.businessinsider.com logoWhy NRX Pharmaceuticals (NRXP) Stock Is Moving Friday?
markets.businessinsider.com - July 23 at 8:15 AM
msn.com logoWhy NRx Pharmaceuticals Stock Is Soaring Today
msn.com - July 22 at 2:43 PM
finance.yahoo.com logoNRx Pharmaceuticals Announces First Successful Commercial Formulation for ZYESAMI™ (aviptadil), Enabling Volume Manufacture, Shipping, and Stockpiling of COVID-19 Medication Subject to Regulatory Approval
finance.yahoo.com - July 22 at 9:43 AM
msn.com logoNRx Pharma Shares Blast Higher on Positive COVID News
msn.com - July 20 at 11:57 AM
nasdaq.com logoNRx Trial Proves Aviptadil Helps Prevent “Cytokine Storm”; Shares Spike 45%
nasdaq.com - July 20 at 11:57 AM
Get NRx Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRXP and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 10/25/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.